Post-COVID-19 Myoclonus-Ataxia Syndrome-Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases?

Movement Disorders Clinical PracticeVolume 10, Issue 4 p. 726-727 LETTERS: PUBLISHED ARTICLES Reply: Post-COVID-19 Myoclonus-Ataxia Syndrome—Is there Really a Need for Intravenous Immunoglobulin Treatment in all Cases? Massimiliano Godani MD, Massimiliano Godani MD Department of Neurology, Sant'Andrea Civic Hospital, ASL 5 Spezzino, La Spezia, ItalySearch for more papers by this authorAlessandro Beronio MD, Alessandro Beronio MD Department of Neurology, Sant'Andrea Civic Hospital, ASL 5 Spezzino, La Spezia, ItalySearch for more papers by this authorGiuseppe Lanza MD, PhD, Corresponding Author Giuseppe Lanza MD, PhD [email protected] orcid.org/0000-0002-5659-662X Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy Clinical Neurophysiology Research Unit, Oasi Research Institute-IRCCS, Troina, Italy Correspondence to: Prof. Giuseppe Lanza, Department of Surgery and Medical-Surgical Specialties, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy; E-mail: [email protected]Search for more papers by this author Massimiliano Godani MD, Massimiliano Godani MD Department of Neurology, Sant'Andrea Civic Hospital, ASL 5 Spezzino, La Spezia, ItalySearch for more papers by this authorAlessandro Beronio MD, Alessandro Beronio MD Department of Neurology, Sant'Andrea Civic Hospital, ASL 5 Spezzino, La Spezia, ItalySearch for more papers by this authorGiuseppe Lanza MD, PhD, Corresponding Author Giuseppe Lanza MD, PhD [email protected] orcid.org/0000-0002-5659-662X Department of Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy Clinical Neurophysiology Research Unit, Oasi Research Institute-IRCCS, Troina, Italy Correspondence to: Prof. Giuseppe Lanza, Department of Surgery and Medical-Surgical Specialties, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy; E-mail: [email protected]Search for more papers by this author First published: 10 February 2023 https://doi.org/10.1002/mdc3.13693Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Filip P, Jarosław S. Post-COVID-19 myoclonus-ataxia syndrome—Is there really a need for intravenous immunoglobulin treatment in all cases? Mov Dis Clin Pract 2023; 10(4): 724–725. doi:10.1002/mdc3.13695 2Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 2022; 29(4): 1243–1253. 3Przytuła F, Błądek S, Sławek J. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. Neurol Neurochir Pol 2021; 55(3): 310–313. 4Godani M, Beronio A, Lanza G. Post-COVID-19 myoclonus-ataxia syndrome responsive to intravenous immunoglobulins. Mov Dis Clin Pract 2022; 9(S2): S6–S8. 5Muccioli L, Pensato U, Bernabè G, et al. Intravenous immunoglobulin therapy in COVID-19-related encephalopathy. J Neurol 2021; 268(8): 2671–2675. Volume10, Issue4April 2023Pages 726-727 This article also appears in:Special Collection: COVID-19 Resources ReferencesRelatedInformation